 |
Board of Directors
Gianna Arnold is a Principal with Miles & Stockbridge, P.C.
Gianna is an experienced entrepreneur and corporate executive, and has first hand knowledge and
practice in matters such as formation, financing, strategic alliances, mergers/acquisitions,
business development; knowledge management including developing and managing intellectual
property portfolios, preparation of business plans/executive summaries, and preparation of
grant proposals. She holds a masters degree (Biotechnology) from Johns Hopkins; a masters degree
(Intellectual Property) from Franklin Pierce Law Center; a juris doctorate from Franklin Pierce
Law Center; and a Business Management Certificate, from University of Utah. Gianna is a frequent
symposium organizer, presenter, and author and has been an active member in WIB for many years,
serving on the Program Committee planning events for the Entrepreneur & Executive Forum and Baltimore.
With 29 years of Biotech and Pharmaceutical experience, Debra Bowes started her own consulting firm in 2006, Chevy Chase BioPartners, specializing in Strategic Planning and Licensing for start-up Life Science companies.
Prior to consulting she was the Head of New Product Planning for MedImmune where she built a department responsible for supporting the commercial and business planning aspects of MedImmune’s R&D pipeline. Prior to MedImmune Debra held the position of Senior Director, Corporate Development for Amylin Pharmaceuticals.
Previously, she spent several years at Pfizer Pharmaceuticals in Licensing and New Product Planning with a focus on oncology. From 1995 to 1998, she served as Worldwide Market Manager for Centocor, where she was responsible for managing and expanding licensing agreements with European and Japanese partners. Debra started her pharmaceutical career with Hybritech, Inc where she held various positions in sales, marketing, market research and licensing. Ms. Bowes holds a Bachelor of Science degree in biology from the University of Cincinnati and a Medical Technologist (M.T.) certification from the American Society of Clinical Pathologists. Debra is a frequent Life Science symposium speaker and has been a Board member and Committee Chair for Women in Bio for several years.
Phyllis Dillinger is the Executive Vice President and
C.F.O. of KPL. KPL manufactures and distributes antibodies and reagents to the Life Science
Research community. During her 13 years with KPL, Ms. Dillinger completed a divestiture,
spun off a separate Genomics business and most recently relocated the organization to a 30,000
square foot state of the art facility. Prior to joining KPL, she was C.F.O. of Sopha Medical
the French held U.S. subsidiary manufacturing gamma cameras for 10 years. During her stay at
Sopha, sales grew from $1M to $42M. She completed a $85M dollar merger between Sopha Medical
and Summit Vision and relocated the new organization to Cleveland, Ohio. Ms. Dillinger holds
an M.B.A. from The George Washington University.
Susan E. Hendrickson is a founding member of Women in Bio and a partner in the intellectual property and technology practice group of Arnold & Porter LLP.
She specializes in licensing and technology transactions and has 15 years of experience in the life sciences industry.
Ms. Hendrickson regularly represents public and private pharmaceutical, biotech, medical device, and other healthcare related companies in connection with their licensing matters and
commercial arrangements. She has advised on life sciences transactions involving all phases of the product life cycle, from early research,
development, and financing efforts, through clinical trials, product approval, manufacturing, marketing and promotion, new market expansions,
and next generation product development. Among other matters, she has represented pharmaceutical and other life sciences companies in connection
with licensing transactions, research and development agreements, clinical trial agreements, co-promotion agreements, feasibility and proof of
concept studies, distribution agreements, manufacturing and supply arrangements, strategic alliances, mergers and acquisitions, product
divestitures, and in connection with the arbitration and settlement of commercial disputes and Hatch-Waxman litigation.
She also has substantial experience in connection with online and electronic healthcare related businesses. She has received recognition in
Chambers and other publications for her expertise in intellectual property and technology transactions.
Cynthia Wong Hu is Vice President, General Counsel and Secretary of EntreMed, Inc. She is
responsible for managing all aspects of EntreMed's legal activities. Prior to joining EntreMed, Ms. Hu served as a
senior attorney for the business finance practice group at Powell Goldstein LLP, in Washington, DC. Before that, Ms. Hu
served as corporate counsel for Golden American Life Insurance Company and was a corporate associate at the law firms of
Klehr, Harrison, Harvey & Branzburg in Philadelphia and Littman & Krooks LLP in New York City. She is currently a
Director of Strathmore Hall Foundation, Inc. and Women in Bio, Inc. Ms. Hu received her J.D. from Rutgers University
School of Law in 1994 and is admitted to the Bar in New York, Pennsylvania and the District of Columbia.
Lynn Johnson Langer is Senior Associate Program Chair Advanced Biotechnology Studies at the Johns Hopkins
University. She has headed the sales and marketing department of several biotechnology companies and worked as a consultant in the bioscience
industry. She founded BioPlan Associates, a management and marketing consulting firm. She has worked extensively with leading biomedical and
high technology companies. Dr. Langer has been involved in "think tanks" with organizations such as NASA, developing potential biotechnology
products to be tested in space and others in the biomedical field. She has published over fifty articles and two book chapters mainly in
business areas of biotechnology and has taught a variety of graduate courses in biotechnology and business. She attended Tulane University
and the University of Maryland for her undergraduate degree in microbiology. She later received her MBA from Johns Hopkins University, and
received the Stegman Award for academic excellence in Administrative Science. She received her Ph.D. in Leadership and Change from Antioch
University. While a student at Johns Hopkins she co-founded the Hopkins Professional Women's Network. Dr. Langer currently teaches Managing
and Leading Biotechnology Professionals, Bioscience Communication, Emerging Issues in Biotechnology and Proseminar in Biotechnology.
She also does executive coaching and management consulting with bioscience organizations.
Robbie Melton is the Senior Program Manager for Entrepreneurial Development at the Maryland Technology Development Corporation (TEDCO). Robbie works directly with technology start up companies to determine the viability and worthiness of the firm for candidacy for TEDCO funding programs and assists companies with other investment opportunities and business needs. She serves on review committees for a number of state funded technology programs and is a director of the MIT Enterprise Forum Board. Robbie has nearly 20 years experience in managing technology development and commercialization projects in a broad range of technologies. For five years she was the operations manager for the Center for Cancer and Transplantation Biology at the Children's National Medical Center. Robbie holds a Master's degree in Science, Technology and Public Policy from The George Washington University.
Carol Nacy, Ph.D. was Executive Vice President and CSO at EntreMed, Inc.
from 1993 through its successful public offering in June 1996. She left EntreMed in November 1996 to establish
Sequella, Inc. and was part-time CSO (1997-98) for Anergen, Inc., a California company focused on autoimmune
diseases. There, she reorganized the scientific staff and approach and positioned the company for acquisition
by Corixa Corp. in December 1998. Dr. Nacy became a full-time CEO and Chair of Sequella and began drawing
salary in January 1999. She is a member of the Board of Directors of several companies(ASMResources, TolerGenics,
Social and Scientific Systems) and non-profit agencies (Sequella Foundation, Women in BIO). Before her business
experience, she was a Career Scientist and Science Manager at the Walter Reed Army Institute of Research and the National Institutes of Health for seventeen years.
Lyn Rossano is a Senior Vice President of Life Sciences at Navigators Management Company.
Her focus is on developing and structuring comprehensive insurance plans for life sciences companies. She specializes in
managing risk for biotechnology, medical device, and pharmaceutical companies, with a coverage concentration in Product
Liability and Errors and Omissions. Ms. Rossano began her insurance career in 1984 as an underwriter for the American
International Group (Lexington Insurance Company) in Boston specializing in healthcare liability and life sciences
liability. Prior to taking a four year hiatus to pursue her doctorate in Epidemiology, she pioneered the field of life
sciences research risk management and liability insurance during her seven year tenure at the CNA Insurance Company in
New York City. Upon returning to the insurance industry, Lyn spent five years with Willis serving as the Life Sciences
Practice Leader for North America for the later three years. She then moved to William Gallagher Associates, a leading
life sciences boutique brokerage firm, where she produced life sciences business throughout North America. Ms. Rossano
is the author of several published scholarly papers based on her research and has presented her work at various academic
conferences. She is also a frequent presenter on the topic of life sciences industry liability and risk management topics
at industry based seminars and conferences. Ms. Rossano holds a Masters Degree in Epidemiology from Columbia University
in New York City. She is currently completing her doctoral degree, also from Columbia University in Epidemiology.
|